NCT07064811 (SPORT-MU) is a NA clinical trial of Exercise Intervention Protocol in Prostate Cancer, sponsored by Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia.

What drugs are being tested in NCT07064811?

Interventions in NCT07064811: Exercise Intervention Protocol, SPoRT-Control Intervention.

What condition does NCT07064811 study?

NCT07064811 studies Prostate Cancer.

Is NCT07064811 still recruiting?

NCT07064811 is currently not yet recruiting. Last updated 15 July 2025.

Last reviewed 2025-07-15 · How we verify

NCT07064811: SPORT-MU

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Standardized Resistance Training Program and Assessment System for Prostate Cancer Patients Receiving Androgen Deprivation Therapy ISPoRT-PCa-ADT Study Protocol for a Randomized Controlled Trial. SPORT-MU

Not yet recruiting NA Last updated 15 July 2025

What this trial tests

NA trial testing Exercise Intervention Protocol in Prostate Cancer in 60 participants. Not yet recruiting.

Timeline

15 November 2025

Primary endpoint
15 February 2027

15 February 2027

Quick facts

Lead sponsor	Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	15 November 2025
Primary completion	15 February 2027
Estimated completion	15 February 2027
Sites	1 location across Spain

Drugs / interventions tested

Exercise Intervention Protocol
SPoRT-Control Intervention

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia — full company profile →

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized controlled trial (RCT) with two parallel study arms evaluated the effectiveness of a 24-week exercise intervention in prostate cancer (PCa) patients under-going androgen deprivation therapy (ADT). Ethical approval was obtained from the Clinical Research Ethics Committee of the University Clinical Hospital "Virgen de la Arrixaca" (Murcia, Spain). Participants were randomly assigned to one of two groups: (1) a supervised progressive resistance training program (SPoRT-PCa-ADT), or (2) a control group receiving a home-based exercise protocol following an initial assessment, accom-panied by weekly telephone follow-up. Assessments were conducted at baseline and at 24 weeks to examine changes in physical, functional, and psychosocial outcomes. Addi-tionally, patient-reported outcomes were collected at the 12-week midpoint (Figure 1). This study design enabled the evaluation of both immediate and sustained intervention effects and facilitated a direct comparison between supervised and home-based exercise approaches

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Standardized Program of Resistance Training for Prostate Cancer Patients Receiving Androgen Deprivation Therapy (SPoRT-PCa-ADT): study protocol for a randomized controlled trial.
Soler-López A, Gómez-Carmona CD, González-Devesa D, López-Plaza D, et al · · 2026 · PMID 42015017 · DOI 10.1186/s12885-026-15902-w

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia trials

Trials by the same sponsor.

NCT06646562 — Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months. · Phase 4 · recruiting
NCT06874907 — First Trimester Prediction of Gestational Diabetes Mellitus by Continuous Glucose Monitoring. · recruiting
NCT06858345 — Study of Maternal and Fetal Cardiovascular Function in Hypertensive States of Pregnancy · recruiting
NCT06713486 — Efficacy of Self-titration of Ventilation in Overlap Syndrome (chronic Obstructive Pulmonar Disease + Sleep Apnea Syndro · NA · not yet recruiting
NCT06449430 — Use of Propofol as a Sedative Agent Versus Spinal Analgesia With Bupivacaine in External Cephalic Version · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07064811 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Last refreshed: 15 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07064811.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing